ArticleCancer drug resistance (Alhambra, Calif.)2024
Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer.
Article in Cancer drug resistance (Alhambra, Calif.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 10 citations in OpenAlex.
- Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review).International journal of molecular medicine · 2026Review
- Review
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- STAMBP drives colorectal cancer progression via CXCR4 deubiquitination and bone marrow-derived suppressor cell recruitment.Genes and immunity · 2026Article
- Circ_0001461 Regulates Colorectal Cancer Growth, Movement and Immune Escape Through miR-532-3p/AMOTL2.Biochemical genetics · 2026Article
- Article
- CircRNA circuits orchestrate lactate metabolism in gastrointestinal cancer progression.Open life sciences · 2026Article
- Esketamine Enhances the Chemosensitivity of Colorectal Adenocarcinoma Cells to 5-Fluorouracil via AMPK/mTOR/HMMR Signaling Pathway.Oncology research · 2026Article
- Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal transduction and targeted therapy · 2025Review
- Review
- Expression Profile of Serum CircFUNDC1 and CircUHRF1 Can Differentiate Between Colorectal Cancer and Inflammatory Bowel Diseases (Ulcerative Colitis and Crohn's Disease).Journal of clinical laboratory analysis · 2025Article
- Circular RNAs: key players in tumor immune evasion.Molecular and cellular biochemistry · 2025Review
- Circular RNAs modulate cancer drug resistance: advances and challenges.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Article
- Upregulated lncRNA LINC01128 in colorectal cancer accelerates cell growth and predicts malignant prognosis through sponging miR-363-3p.Journal of cancer research and clinical oncology · 2024Article
- Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.